Skip to main content
. 2017 Mar 9;12(3):e0173354. doi: 10.1371/journal.pone.0173354

Fig 2. Thyroid cancer-specific survival rates for the three groups of patients with bone metastasis.

Fig 2

The disease-specific survival rates for groups A, B, and for all patients included in the study were 53.4%, 85.0%, and 63.5% at 5 years; 22.9%, 64.2%, and 36.7% at 10 years; 9.4%, 37.3%, and 18.2% at 20 years; and 3.7%, 37.3%, and 10.8% at 30 years, respectively. The difference in disease-specific mortality rates between groups A and B was significant difference (p < 0.0001).